Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel Free SN Stock Alerts

Smith & Nephew (SN) Competitors

Smith & Nephew logo
GBX 1,113 +15.00 (+1.37%)
As of 08/7/2026
Compare

SN vs. CTEC, AMS, NIOX, TSTL, and EKF

Should you buy Smith & Nephew stock or one of its competitors? MarketBeat compares Smith & Nephew with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smith & Nephew include ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), Tristel (TSTL), and EKF Diagnostics (EKF). These companies are all part of the "healthcare equipment & supplies" industry.

How does Smith & Nephew compare to ConvaTec Group?

Smith & Nephew (LON:SN) and ConvaTec Group (LON:CTEC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 68.4% of ConvaTec Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by insiders. Comparatively, 1.0% of ConvaTec Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ConvaTec Group had 5 more articles in the media than Smith & Nephew. MarketBeat recorded 19 mentions for ConvaTec Group and 14 mentions for Smith & Nephew. ConvaTec Group's average media sentiment score of 0.57 beat Smith & Nephew's score of -0.31 indicating that ConvaTec Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
ConvaTec Group
4 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Smith & Nephew presently has a consensus target price of GBX 1,172.56, indicating a potential upside of 5.35%. ConvaTec Group has a consensus target price of GBX 306, indicating a potential upside of 31.67%. Given ConvaTec Group's stronger consensus rating and higher possible upside, analysts clearly believe ConvaTec Group is more favorable than Smith & Nephew.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
ConvaTec Group
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Smith & Nephew has a net margin of 10.08% compared to ConvaTec Group's net margin of 4.99%. Smith & Nephew's return on equity of 12.25% beat ConvaTec Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew10.08% 12.25% 4.51%
ConvaTec Group 4.99%8.40%5.01%

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.6%. ConvaTec Group pays an annual dividend of GBX 6.77 per share and has a dividend yield of 2.9%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 78.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew has higher revenue and earnings than ConvaTec Group. ConvaTec Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£7.08B1.72£382.79M£27.7740.07
ConvaTec Group£2.49B1.82£188.35M£8.6027.02

Smith & Nephew has a beta of 0.688, indicating that its share price is 31% less volatile than the broader market. Comparatively, ConvaTec Group has a beta of 0.765, indicating that its share price is 24% less volatile than the broader market.

Summary

ConvaTec Group beats Smith & Nephew on 12 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Smith & Nephew has higher revenue and earnings than Advanced Medical Solutions Group. Smith & Nephew is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.17
Smith & Nephew£7.08B1.72£382.79M£27.7740.07

22.7% of Advanced Medical Solutions Group shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 4.0% of Advanced Medical Solutions Group shares are held by insiders. Comparatively, 0.2% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Advanced Medical Solutions Group presently has a consensus price target of GBX 270.25, suggesting a potential downside of 3.83%. Smith & Nephew has a consensus price target of GBX 1,172.56, suggesting a potential upside of 5.35%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.6%. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Smith & Nephew had 14 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 14 mentions for Smith & Nephew and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.00 beat Smith & Nephew's score of -0.31 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company Overall Sentiment
Advanced Medical Solutions Group Neutral
Smith & Nephew Neutral

Smith & Nephew has a net margin of 10.08% compared to Advanced Medical Solutions Group's net margin of 4.35%. Smith & Nephew's return on equity of 12.25% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group4.35% 3.87% 2.35%
Smith & Nephew 10.08%12.25%4.51%

Advanced Medical Solutions Group has a beta of 0.701, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, meaning that its stock price is 31% less volatile than the broader market.

Summary

Smith & Nephew beats Advanced Medical Solutions Group on 11 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to NIOX Group?

Smith & Nephew (LON:SN) and NIOX Group (LON:NIOX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Smith & Nephew has a beta of 0.688, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

In the previous week, Smith & Nephew had 13 more articles in the media than NIOX Group. MarketBeat recorded 14 mentions for Smith & Nephew and 1 mentions for NIOX Group. NIOX Group's average media sentiment score of 0.00 beat Smith & Nephew's score of -0.31 indicating that NIOX Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
2 Very Negative mention(s)
Neutral
NIOX Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NIOX Group has lower revenue, but higher earnings than Smith & Nephew. NIOX Group is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew£7.08B1.72£382.79M£27.7740.07
NIOX Group£48.70M5.38£995.88M£1.6437.93

NIOX Group has a net margin of 14.37% compared to Smith & Nephew's net margin of 10.08%. Smith & Nephew's return on equity of 12.25% beat NIOX Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & Nephew10.08% 12.25% 4.51%
NIOX Group 14.37%10.14%3.95%

Smith & Nephew presently has a consensus target price of GBX 1,172.56, suggesting a potential upside of 5.35%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 38.26%. Given NIOX Group's stronger consensus rating and higher probable upside, analysts plainly believe NIOX Group is more favorable than Smith & Nephew.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.6%. NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 2.0%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Smith & Nephew and NIOX Group tied by winning 9 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to Tristel?

Tristel (LON:TSTL) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Smith & Nephew has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.97£6.54M£16.2425.25
Smith & Nephew£7.08B1.72£382.79M£27.7740.07

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.6%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Smith & Nephew has a consensus price target of GBX 1,172.56, suggesting a potential upside of 5.35%. Given Smith & Nephew's stronger consensus rating and higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Smith & Nephew had 14 more articles in the media than Tristel. MarketBeat recorded 14 mentions for Smith & Nephew and 0 mentions for Tristel. Tristel's average media sentiment score of 0.00 beat Smith & Nephew's score of -0.31 indicating that Tristel is being referred to more favorably in the media.

Company Overall Sentiment
Tristel Neutral
Smith & Nephew Neutral

Tristel has a net margin of 15.88% compared to Smith & Nephew's net margin of 10.08%. Tristel's return on equity of 23.64% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Smith & Nephew 10.08%12.25%4.51%

22.5% of Tristel shares are owned by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 0.2% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tristel has a beta of 0.346, meaning that its share price is 65% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, meaning that its share price is 31% less volatile than the broader market.

Summary

Smith & Nephew beats Tristel on 10 of the 18 factors compared between the two stocks.

How does Smith & Nephew compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Smith & Nephew (LON:SN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 34.62%. Smith & Nephew has a consensus price target of GBX 1,172.56, suggesting a potential upside of 5.35%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, equities analysts clearly believe EKF Diagnostics is more favorable than Smith & Nephew.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Smith & Nephew had 14 more articles in the media than EKF Diagnostics. MarketBeat recorded 14 mentions for Smith & Nephew and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of 0.00 beat Smith & Nephew's score of -0.31 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Neutral
Smith & Nephew Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 62.2% of Smith & Nephew shares are held by institutional investors. 40.0% of EKF Diagnostics shares are held by company insiders. Comparatively, 0.2% of Smith & Nephew shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Smith & Nephew has a net margin of 10.08% compared to EKF Diagnostics' net margin of 4.12%. Smith & Nephew's return on equity of 12.25% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Smith & Nephew 10.08%12.25%4.51%

EKF Diagnostics has a beta of 0.513, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Smith & Nephew has a beta of 0.688, suggesting that its stock price is 31% less volatile than the broader market.

Smith & Nephew has higher revenue and earnings than EKF Diagnostics. Smith & Nephew is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.17£4.68M£0.4755.32
Smith & Nephew£7.08B1.72£382.79M£27.7740.07

Summary

Smith & Nephew beats EKF Diagnostics on 9 of the 16 factors compared between the two stocks.

Get Smith & Nephew News Delivered to You Automatically

Sign up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SN vs. The Competition

Export
MetricSmith & NephewHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£12.20B£5.86B£7.02B£2.88B
Dividend Yield3.66%1.78%2.58%6.12%
P/E Ratio40.0724.26270.57368.42
Price / Sales1.7268.30599.8883,672.22
Price / Cash18.6833.5528.8927.89
Price / Book1.876.1111.217.20
Net Income£382.79M£149.01M£3.45B£5.89B
7 Day Performance-3.93%2.54%3.41%1.45%
1 Month Performance-1.55%0.78%-0.71%2.26%
1 Year Performance-16.97%4.93%77.31%74.55%

Smith & Nephew Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SN
Smith & Nephew
2.1536 of 5 stars		GBX 1,113
+1.4%		GBX 1,172.56
+5.4%		-17.0%£12.20B£7.08B40.0718,452
CTEC
ConvaTec Group
4.8009 of 5 stars		GBX 224.60
-2.1%		GBX 306
+36.2%		+1.5%£4.39B£2.44B26.1210,000
AMS
Advanced Medical Solutions Group
N/AGBX 280.50
flat		GBX 270.25
-3.7%		+32.5%£609.77M£228.94M62.0610
NIOX
NIOX Group
2.547 of 5 stars		GBX 62.17
+1.6%		GBX 86
+38.3%		-12.6%£261.66M£48.70M37.9192
TSTL
Tristel
N/AGBX 415
-2.4%		N/A+7.9%£199.19M£49.54M25.55208

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SN) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
AI Bubble Could Finally Be Done - Wall St's Warning
Wall Street analysts are warning that the AI-driven market rally may be nearing its limits, with some cautioni...
TradeSmith | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
Trump's Next Move Could Shrink Your Dollar
There's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...
Priority Gold | Sponsoredtc pixel
I’ll Keep This Short… (Huge AI Opportunity)
Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...
Traders Agency | Sponsoredtc pixel